High-dose chemotherapy for patients with high-risk breast cancer: A clinical and economic assessment using a quality-adjusted survival analysis

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 2, 2008, Pages 117-124

  Marino, Patricia ^a,b,c   Roché, Henri ^d   Moatti, Jean Paul ^a,b  

^a INSERM   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d INSTITUT CLAUDIUS REGAUD   (France)

Author keywords

Breast cancer; Economic analysis; High dose chemotherapy; Quality adjusted survival

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TAMOXIFEN;

ADULT; ANOREXIA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONSTIPATION; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG DOSE REGIMEN; DRUG MEGADOSE; DYSPNEA; FATIGUE; FEMALE; HEALTH CARE COST; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; PAIN; Q TWIST ANALYSIS; QUALITY ADJUSTED LIFE YEAR; VOMITING;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; DRUG TOXICITY; FEMALE; HUMANS; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 42049121517     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181573e83     Document Type: Article

References (34)

1. Rodenhuis S, Richel DJ, van der Wall E, et al. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet. 1998;352:515-521.
2. Hortobagyi GN, Buzdar AU, Theriault RL, et al. Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst. 2000;92:225-233.
3. Bergh J, Wiklund T, Erikstein B, et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet. 2000;356:1384-1391.
4. Peters WJ, Dansey RD, Klein JL, et al. High dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer. Oncologist. 2005;5:1-13.
5. Rodenhuis S, Bontenbal M, Beex LV, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med. 2003;349:7-16.
6. Tallman MS, Gray R, Robert NJ, et al. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med. 2003;349:17-26.
7. Nitz UA, Mohrmann S, Fischer J, et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet. 2005;366:1935-1944.
8. Macquart-Moulin G, Viens P, Palangie T, et al. High-dose sequential chemotherapy with recombinant granulocyte colony-stimulating factor and repeated stem-cell support for inflammatory breast cancer patients: does impact on quality of life jeopardize feasibility and acceptability of treatment? J Clin Oncol. 2000;18:754-764.
9. Partridge AH, Bunnell CA, Winer EP. Quality of life issues among women undergoing high-dose chemotherapy for breast cancer. Breast Dis. 2001;14:41-50.
10. Astier M, Mayordomo J, Abad J, Gomez L, Tres A. Cost Analysis of high-dose chemotherapy and blood stem-cell support in patients with solid tumors. Ann Oncol. 2000;11:603-606.
11. De Rosa L, Lalle M, Pandolfi A, Pescador L. Costs of high-dose chemotherapy and peripheral blood progenitor cell autograft for breast cancer. Bone Marrow Transpl. 2001;27:1031-1035.
12. Marino P, Siani C, Roche H, Moatti JP. Impact of uncertainty on cost-effectiveness analysis of medical strategies: the case of high-dose chemotherapy for breast cancer patients. Int J Technol Assess Health Care. 2005;21:342-350.
13. Goldhirsch A, Gelber RD, Simes RJ, Glasziou P, Coates AS. Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis. J Clin Oncol. 1989;7:36-44.
14. Gelber RD, Gelman RS, Goldhirsch A. A quality-of-life-oriented end-point for comparing therapies. Biometrics. 1989;45:781-795.
15. Glasziou P, Simes R, Gelber R. Quality adjusted survival analysis. Stat Med. 1990;9:1259-1276.
16. Kilbridge KL, Cole BF, Kirkwood JM, et al. Quality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial data. J Clin Oncol. 2002;20:1311-1318.
17. Le Corroller A, Moatti J, Chabannon C, et al. Optimization of peripheral blood stem cell collection by leukopheresis. Interaction between economic and clinical assessment of an innovation. Int J Technol Assess Health Care. 1999;15:161-172.
18. Bercez C, Lebrun T, Bonneterre ME, Selke B, Lenne X, Bonneterre J. [Advanced breast cancer: an evaluation of the cost of recurrence]. Bull Cancer. 1999;86:585-590.
19. Radice D, Redaelli A. Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer. Pharmacoeconomics. 2005;23:69-75.
20. Fairclough DL, Fetting JH, Cella D, Wonson W, Moinpour CM. Quality of life and quality adjusted survival for breast cancer patients receiving adjuvant therapy. Eastern Cooperative Oncology Group (ECOG). Qual Life Res. 1999;8:723-731.
21. Trippoli S, Becagli P, Messori A. Adjuvant cyclophosphamide, methotrexate and fluorouracil for node-positive breast cancer: a lifetime cost-utility analysis based on a modified Q-TWiST method. Eur J Clin Pharmacol. 1997;53:281-282.
22. Goldhirsch A; for the International Breast Cancer Study Group. Cole BF, Gelber RD, A quality-adjusted survival meta-analysis of adjuvant chemotherapy for premenopausal breast cancer. Stat Med. 1995;14:1771-1784.
23. Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A. Polychemotherapy for early breast cancer: an overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet. 2001;358:277-286.
24. Kefford RF. Adjuvant therapy of cutaneous melanoma: the interferon debate. Ann Oncol. 2003;14:358-365.
25. Porcher R, Levy V, Fermand JP, et al. Evaluating high dose therapy in Multiple Myeloma: use of quality-adjusted survival analysis. Qual Life Res. 2002;11:91-99.
26. Wirt DP, Giles FJ, Oken MM, Solal-Celigny P, Beck JR. Cost-Effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma. Leuk Lymphoma. 2001;40:565-579.
27. Mounier N, Haioun C, Cole BF, et al. Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA). Blood. 2000;95:3687-3692.
28. Jansen Hjermstad M, Kaasa S. Quality of life in adult cancer patients treated with bone marrow transplantation - a review of the literature. Eur J Cancer. 1995;31A:163-173.
29. Ravdin PM, Siminoff IA, Harvey JA. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol. 1998;16:515-521.
30. Jansen SJ, Kievit J, Nooij MA, et al. Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile? Br J Cancer. 2001;84:1577-1585.
31. Pearson S, Rawlins M. Quality, innovation, and value for money: NICE and the British National Health Service. JAMA. 2005;294:2618-2622.
32. Marino P, Roché H, Moatti JP. Deterioration of quality of life (QOL) of high-risk breast cancer patients treated with high dose versus standard chemotherapy: the PEGASE 01 QOL study. Value in Health. In press.
33. Lohr KN. Health outcomes methodology symposium: summary and recommendations. Med Care 2000;38:II194-II208.
34. Mounier N, Ferme C, Flechtner H, Henzy-Amar M, Lepage E. Model-based methodology for analyzing incomplete quality-of-life data and integrating them into the Q-TWiST framework. Med Decis Making. 2003;23:54-66.